Cathelicidin antimicrobial peptides with reduced activation of toll-like receptor signaling have potent bactericidal activity against colistin-resistant bacteria

mBio

Volumn 7, Issue 5, 2016, Pages

  Kao, Cheng ^a   Lin, Xiaoyan ^a   Yi, Guanghui ^a   Zhang, Yunliang ^a   Rowe Magnus, Dean A ^a   Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; COLISTIN; INTERLEUKIN 6; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; ANTIMICROBIAL CATIONIC PEPTIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE; POLYMYXIN;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM; COLISTIN RESISTANT BACTERIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXICITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HEMOLYSIS; HUMAN; HUMAN CELL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; ANIMAL; ANTIBIOTIC RESISTANCE; CELL DEATH; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ERYTHROCYTE; GENETICS; GRAM NEGATIVE BACTERIUM; IMMUNOLOGY; INFLAMMATION; METABOLISM; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATHELICIDINS; CELL DEATH; COLISTIN; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; ERYTHROCYTES; GRAM-NEGATIVE BACTERIA; HUMANS; INFLAMMATION; MICROBIAL SENSITIVITY TESTS; POLYMYXINS; TOLL-LIKE RECEPTORS;

EID: 84994399644     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01418-16     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA
2. World Health Organization. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland
3. Department of Health Antimicrobial Resistance Strategy Analytical Working Group. 2015. Antimicrobial resistance empirical and statistical evidence-base. Antimicrobial Resistance Strategy Analytical Working Group, Department of Health, London, England
4. President’s Council of Advisors on Science and Technology. 2014. Report to the president on combating antibiotic resistance. September 2014. President’s Council of Advisors on Science and Technology, Executive Office of the President, Washington DC
5. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16: 161-168. http://dx.doi.org/10.1016/S1473-3099(15)00424-7
6. Skov RL, Monnet DL. 2016. Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds. Euro Surveill 21(9): pii 30155. http://dx.doi.org/10.2807/1560-7917.ES.2016.21.9.30155
7. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, Hinkle M, Whitman T, Lesho E, Schaecher KE. 20 June 2016. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother. Epub ahead of print. http://dx.doi.org/10.1128/AAC.01103-16
8. Du H, Chen L, Tang Y, Kreiswirth BN. 2016. Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 16:287-288. http://dx.doi.org/10.1016/S1473-3099(16)00056-6
9. Wang G, Mishra B, Lau K, Lushnikova T, Golla R, Wang X. 2015. Antimicrobial peptides in 2014. Pharmaceuticals (Basel) 8:123-150. http://dx.doi.org/10.3390/ph8010123
10. Kościuczuk EM, Lisowski P, Jarczak J, Strzałkowska N, Jóźwik A, Horbańczuk J, Krzyzewski J, Zwierzchowski L, Bagnicka E. 2012. Cathelicidins: family of antimicrobial peptides, a review. Mol Biol Rep 39:10957-10970. http://dx.doi.org/10.1007/s11033-012-1997-x
11. Nguyen LT, Haney EF, Vogel HJ. 2011. The expanding scope of antimicrobial peptide structures and their mode of action. Trends Biotechnol 29:464-471. http://dx.doi.org/10.1016/j.tibtech.2011.05.001
12. Zanetti M, Gennaro R, Romeo D. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1-5. http://dx.doi.org/10.1016/0014-5793(95)01050-O
13. Fukumoto K, Nagaoka I, Yamataka A, Kobayashi H, Yanai T, Kato Y, Miyano T. 2005. Effects of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr Surg Int 21:20-24. http://dx.doi.org/10.1007/s00383-004-1256-x
14. Filewod NCJ, Pistolic J, Hancock REW. 2009. Low concentrations of LL-37 alter IL-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli. FEMS Immunol Med Microbiol 56:233-240. http://dx.doi.org/10.1111/j.1574-695X.2009.00571.x
15. Vetrano S, Genua M. 2015. Cathelicidins: a novel therapy for the treatment of intestinal fibrosis? Cell Mol Gasteroenterol Hepatol 2015:2-3. http://dx.doi.org/10.1016/j.jcmgh.2014.12.001
16. Yoo JH, Ho S, Tran DH, Cheng M, Bakirtzi K, Kubota Y, Ichikawa R, Su B, Tran DH, Hing TC, Chang I, Shih DQ, Issacson RE, Gallo RL, Fiocchi C, Pothoulakis C, Koon HW. 2015. Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis. Cell Mol Gasterol Hepatol 1:55-74.e1
17. Takahashi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Yoshizaki A, Tamaki Z, Tada Y, Sugaya M, Kadona T, Sato S. 23 April 2016. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. Br J Dermatol. Epub ahead of print. http://dx.doi.org/10.1111/bjd.14699
18. Lai Y, Adhikarakunnathu S, Bhardwaj K, Ranjith-Kumar CT, Wen Y, Jordan JL, Wu LH, Dragnea B, San Mateo L, Kao CC. 2011. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS One 6:e26632. http://dx.doi.org/10.1371/journal.pone.0026632
19. Wang G. 2008. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem 283:32637-32643. http://dx.doi.org/10.1074/jbc.M805533200
20. Singh D, Qi R, Jordan JL, San Mateo L, Kao CC. 2013. The human antimicrobial peptide LL-37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I:C) through a FPRL1-dependent pathway. J Biol Chem 288:8258-8268. http://dx.doi.org/10.1074/jbc.M112.440883
21. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M. 2011. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 3:73ra19. http://dx.doi.org/10.1126/scitranslmed.3001180
22. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schröder JM, Liu YJ, Gilliet M. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-569. http://dx.doi.org/10.1038/nature06116
23. Dombrowski Y, Schauber J. 2012. Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 21:327-330. http://dx.doi.org/10.1111/j.1600-0625.2012.01459.x
24. Singh D, Vaughan R, Kao CC. 2014. LL-37 enhancement of signal transduction by Toll-like receptor 3 is regulated by pH: identification of a peptide antagonist of LL-37. J Biol Chem 289:27614-27624. http://dx.doi.org/10.1074/jbc.M114.582973
25. Wang G, Li X, Wang Z. 2016. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res 44:D1087-D1093. http://dx.doi.org/10.1093/nar/gkv1278
26. Janda JM, Newton AE, Bopp CA. 2015. Vibriosis. Clin Lab Med 35: 273-288. http://dx.doi.org/10.1093/nar/gkv1278
27. Bartolomé B, Jubete Y, Martínez E, de la Cruz F. 1991. Construction and properties of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives. Gene 102:75-78. http://dx.doi.org/10.1016/0378-1119(91)90541-I
28. Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS. 2013. Clinical use of colistin induces crossresistance to host antimicrobials in Acinetobacter baumannii. mBio 4:e00021-13. http://dx.doi.org/10.1128/mBio.00021-13
29. Fleitas O, Franco OL. 2016. Induced bacterial cross-resistance toward host antimicrobial peptides: a worrying phenomenon. Front Microbiol 7:381. http://dx.doi.org/10.3389/fmicb.2016.00381
30. Skerlava B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. 1996. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 45:28375-28381
31. Wang G, Hanke ML, Mishra B, Lushnikova T, Heim CE, Thomas VC, Bayles KW, Kielian T. 2014. Transformation of human cathelicidin LL-37 into selective, stable, and potent antimicrobial compounds. ACS Chem Biol 9:1997-2002. http://dx.doi.org/10.1021/cb500475y
32. Sood R, Domanov Y, Pietiäinen M, Kontinen VP, Kinnunen PK. 2008. Binding of LL-37 to model biomembranes: insight into target vs host cell recognition. Biochim Biophys Acta 1778:983-996. http://dx.doi.org/10.1016/j.bbamem.2007.11.016
33. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. 1999. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its noncell-selective activity. Biochem J 341:501-513. http://dx.doi.org/10.1042/bj3410501
34. Peschel A. 2002. How do bacteria resist human antimicrobial peptides? Trends Microbiol 10:179-186. http://dx.doi.org/10.1016/S0966-842X(02)02333-8
35. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. 2013. Pharmacology of polymyxins: new insights into an “old” class of antibiotics. Future Microbiol 8:711-724. http://dx.doi.org/10.2217/fmb.13.39
36. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 5:643. http://dx.doi.org/10.3389/fmicb.2014.00643
37. Ranjith-Kumar CT, Duffy KE, Jordan JL, Eaton-Bassiri A, Vaughan R, Hoose SA, Lamb RJ, Sarisky RT, Kao CC. 2008. Single-stranded oligonucleotides can inhibit cytokine production induced by the human Tolllike receptor 3. Mol Cell Biol 112:4507-4519. http://dx.doi.org/10.1128/MCB.00308-08
38. Cole C, Barber JD, Barton GJ. 2008. The Jpred 3 secondary structure prediction server. Nucleic Acids Res 36(Suppl 2):W197-W201. http://dx.doi.org/10.1093/nar/gkn238
39. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing, 24th informational supplement. CLSI Document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.